Keep up-to-date with PrECOG by visiting our news page regularly.
The results from the PrE0204 trial, A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma was published by Sahai V, Catalano P, Zalupski MM, et.al. The article appeared online before print in JAMA Oncology on Aug 30, 2018. [NCT02181634, doi: 10.1001/jamaoncol.2018.3277].
Now Open to Enrollment: PrE0404 A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma. NCT03323151
Now Open to Enrollment: PrE0403 Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy. NCT03113422
The results from the PrE0102 study, a Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy was published by Kornblum N, Zhao F, Manola J, et.al. The article appeared online before print in the Journal of Clinical Oncology on April […]